PRASCEND DIN 02412217
Status: Marketed
Holder: BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC.
Molecule: PERGOLIDE (PERGOLIDE MESYLATE)
Health Canada record
| Active ingredient(s) | PERGOLIDE (PERGOLIDE MESYLATE) 1 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Veterinary |
| ATC | |
| Original market date | 10-Feb-2014 |
| Current status date | 10-Jun-2021 |
| Source | Health Canada DPD |
Establishment licence of the holder
Boehringer Ingelheim (Canada) Ltd Ltee — licence 100187, currently licensed, last inspection rating C (2025-03-03).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing PERGOLIDE (PERGOLIDE MESYLATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 01934279 | PERMAX TAB 0.05MG | ELI LILLY CANADA INC | Tablet | PERGOLIDE (PERGOLIDE MESYLATE) 0.05 MG | Cancelled Post Market |
| 01934287 | PERMAX TAB 0.25MG | ELI LILLY CANADA INC | Tablet | PERGOLIDE (PERGOLIDE MESYLATE) 0.25 MG | Cancelled Post Market |
| 01934295 | PERMAX TAB 1MG | ELI LILLY CANADA INC | Tablet | PERGOLIDE (PERGOLIDE MESYLATE) 1 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 26046 | 2021-06-10 | New Drug Submission (NDS) | CHANGE IN PRODUCT OWNERSHIP |
| 14700 | 2013-09-05 | New Drug Submission (NDS) |